During the corresponding time, Bruker Corporation recorded a revenue increase by 5.22 % year on year, sequentially revenue grew by 1.91 %. While revenue at the Bruker Corporation's corporate clients
Bruker's Comment on Sales, Marketing and Customers
The company provides products for detecting, measuring, and visualizing chemical, biological, and industrial material samples at microscopic, molecular, and cellular levels. Its offerings support life and materials science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics, and nanotechnology. Market segments served include post-genomic life science molecular and cell biology research, preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, clinical microbiology, and molecular diagnostics. The BSI BioSpin segment focuses on oncology, neurology, cardiology, inflammation, infectious diseases, cancer research, functional and anatomical neuroimaging, orthopedics, cardiac imaging, and stroke models. The Biopharma and Applied division serves pharmaceutical and biotechnology, cleantech, industrial, and clinical markets. Additionally, the company offers services and lifecycle support to complement its instruments and solutions.
Bruker Corporation (Nasdaq: BRKR), a leading innovator in scientific instrumentation, has recently announced a series of significant advancements that underscore its commitment to enhancing research capabilities in spatial proteomics and drug discovery. These developments aim to propel Bruker to the forefront of life sciences technology, with the unveiling of EpicIF™ technology for its CellScape platform, a strategic investment in NovAliX, and the resolution of an injunction affecting its NanoString business in Germany. EpicIF™ Technology: A Game Changer in Spatial ProteomicsAt the heart of Bruker’s latest announcement is the introduction of EpicIF™, a revolutionary fluorescence signal removal techno...
In a strategic move aimed at enhancing its competitive edge in the rapidly evolving field of life sciences, Bruker Corporation has announced the establishment of its new Bruker Spatial Biology division. Based in Billerica, Massachusetts, this division unites three key elements of Bruker’s operational portfolio: the businesses of NanoString Technologies and Canopy Biosciences, along with its subsidiary, Bruker Spatial Genomics, Inc. (formerly Acuity Spatial Genomics). This ambitious decision signifies Bruker s commitment to providing what it claims to be the most diverse and comprehensive solutions in spatial biology, a burgeoning field that marries genomics and imaging to elucidate the complexities of biol...
The Intersection of Innovation and Collaboration: Bruker’s Strategic Moves in Drug Discovery and Diagnostics In the rapidly evolving landscape of biomedicine, few companies are as poised to make a significant impact as Bruker Corporation (NASDAQ: BRKR). Renowned for its cutting-edge scientific instruments and analytical technologies, Bruker is doubling down on innovation and collaboration through strategic investments and partnerships aimed at enhancing drug discovery and cancer diagnostics. Strategic Minority Investment in NovAliXBruker’s recent announcement regarding a minority investment in NovAliX, a preclinical Contract Research Organization (CRO) based in Strasbourg, France, underscores its commitm...
Innovative Collaboration and Strategic Moves Propel Bruker and Cellens to the Forefront of Cancer Detection and Biophysical ResearchIn a groundbreaking partnership, Cellens, Inc., an early-stage cancer diagnostic company, and Bruker BioAFM, a division of Bruker Corporation (Nasdaq: BRKR), have announced a collaboration aimed at pioneering clinical diagnostic tests that utilize multi-parametric, single-cell biophysical markers combined with machine learning. This alliance leverages the advanced capabilities of Bruker s atomic force microscopy (AFM) to attain cellular biophysical markers, promising to revolutionize early cancer detection.Cellens innovative approach integrates mechanobiology and machine learn...
Bruker Corporation, a leading provider of scientific instruments and solutions, recently unveiled its groundbreaking neofleX MALDI-TOF/TOF system at the 72nd ASMS meeting in Anaheim, California. This innovative system is designed to facilitate tissue imaging using mass spectrometry, ultimately enabling research in the field of spatial biology. With the introduction of the neofleX Imaging Profiler, Bruker aims to bring significant advancements in MALDI-TOF technology by providing enhanced performance and a more user-friendly laboratory tool.Key Features of the neofleX MALDI-TOF System:The neofleX MALDI-TOF/TOF system offers unprecedented capabilities in mass spectrometry-based tissue imaging. Perhaps, one of ...
Bruker’s Comment on Sales, Marketing and Customers
The company provides products for detecting, measuring, and visualizing chemical, biological, and industrial material samples at microscopic, molecular, and cellular levels. Its offerings support life and materials science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics, and nanotechnology. Market segments served include post-genomic life science molecular and cell biology research, preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, clinical microbiology, and molecular diagnostics. The BSI BioSpin segment focuses on oncology, neurology, cardiology, inflammation, infectious diseases, cancer research, functional and anatomical neuroimaging, orthopedics, cardiac imaging, and stroke models. The Biopharma and Applied division serves pharmaceutical and biotechnology, cleantech, industrial, and clinical markets. Additionally, the company offers services and lifecycle support to complement its instruments and solutions.
Sources:
Bruker Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Bruker Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Bruker Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
156.24 %